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Abstract
Background: FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients with chronic hepatitis C (CHC).
The aim was to test two hypotheses, one, that the FT diagnostic value was similar in the three other frequent fibrotic
diseases: chronic hepatitis B (CHB), alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD); and the
other, that the FT diagnostic value was similar for intermediate and extreme fibrosis stages.
Methods: The main end points were the FT area under the ROC curves (AUROCs) for the diagnosis of bridging fibrosis
(F2F3F4 vs. F0F1), standardized for the spectrum of fibrosis stages, and the comparison of FT AUROCs between adjacent
stages. Two meta-analyses were performed: one combining all the published studies (random model), and one of an
integrated data base combining individual data. Sensitivity analysis integrated the independency of authors, lenght of
biopsy, prospective design, respect of procedures, comorbidities, and duration between biopsy and serum sampling.
Results: A total of 30 studies were included which pooled 6,378 subjects with both FT and biopsy (3,501 HCV, 1,457
HBV, 267 NAFLD, 429 ALD, and 724 mixed). Individual data were analyzed in 3,282 patients. The mean standardized
AUROC was 0.84 (95% CI, 0.83–0.86), without differences between causes of liver disease: HCV 0.85 (0.82–0.87), HBV
0.80 (0.77–0.84), NAFLD 0.84 (0.76–0.92), ALD 0.86 (0.80–0.92), mixed 0.85 (0.80–0.93). The AUROC for the diagnosis
of the intermediate adjacent stages F2 vs. F1 (0.66; 0.63–0.68, n = 2,055) did not differ from that of the extreme stages
F3 vs. F4 (0.69; 0.65–0.72, n = 817) or F1 vs. F0 (0.62; 0.59–0.65, n = 1788).
Conclusion: FibroTest is an effective alternative to biopsy in patients with chronic hepatitis C and B, ALD and NAFLD.
The FT diagnostic value is similar for the diagnosis of intermediate and extreme fibrosis stages.
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Background
Fibrotest (FT) is a biomarker of liver fibrosis which was
initially validated in patients with chronic hepatitis C
(HCV) [1] and then in the three other common fibrotic
liver diseases: [2] chronic hepatitis B (HBV) [3,4], alco-
holic liver disease (ALD) [5-7] and non-alcoholic fatty
liver disease (NAFLD) [8].
FT is widely used as a non invasive alternative to liver
biopsy, with 190,000 tests ordered between September
2002 and April 2007 (Biopredictive data on file, Jean
Marie Castille, personal communication); however, two
main critiques are often made by experts: 1) FT has been
mainly studied in chronic hepatitis C, and 2) the FT diag-
nostic value is lower for intermediate fibrosis stages
(bridging vs. non bridging fibrosis) than for extreme
stages (no fibrosis or cirrhosis)[9,10]. In this latter cri-
tique, which is also true for liver biopsy, there is a risk of
confusion between adjacent stages and intermediate
stages or an absence of taking into account the prevalence
of fibrosis stages defining advanced and non-advanced
fibrosis [11,12].
The aim of this meta-analysis was to test two hypotheses,
first, that the FT diagnostic value was similar in patients
with HCV and in patients with the three other frequent
fibrotic diseases; and second, that the FT diagnostic value
was similar for intermediate and extreme stages.
Methods
Design
Two meta-analyses were performed; one combined all the
published studies (random model), and the other used an
integrated database combining individual data provided
by authors.
To select published studies we used the Standards for
Reporting of Diagnostic Accuracy (STARD) criteria and
the Cochrane Database of Systematic Reviews (CDSR)
methods [13]. Key STARD criteria include factors such as
whether: 1) the study population was relevant to the clin-
ical question being addressed; 2) there was a careful
description of the population from which the patients
were drawn, as well as actual inclusions and exclusions; 3)
recruitment and the mode of sampling were carefully
described; 4) researchers interpreting the non-invasive test
were blinded to the reference test result; and 5) sufficient
data were provided to complete a 2 × 2 table of true and
false positive and negative diagnoses. Studies published
only with an abstract provided insufficient data and were
excluded  [14].
Search strategy
We searched MEDLINE with the key word "FibroTest". We
hand-searched key journals (Gastroenterology, Hepatology,
Journal of Hepatology, Gut, Journal of Viral hepatitis and
American Journal of Gastroenterology) from February 2001
to April 2007 to validate the search, as well as the abstract
books of the American Association and European Associ-
ation for the Study of Liver Disease annual meetings.
Inclusion and exclusion criteria
Two reviewers (a hepatologist and a hepatologist-statisti-
cian) independently assessed the papers with predeter-
mined STARD criteria. Disagreements were resolved
through discussion with a third reviewer. The decision as
to inclusion or exclusion was not related to results.
We excluded all studies except those that: included
patients with chronic liver diseases; stated that all patients
had had the FT and liver biopsy; provided data for true
positives and negatives, false positives and negatives and
AUROCs for advanced fibrosis; stated that the FT had
been assessed blind to the biopsy; and stated the method
used for defining the degree of fibrosis. We were careful to
avoid including data from duplicate publications.
Data extraction
To allow comparisons between causes of liver disease in
the studies, we categorized them into 5 classes: patients
with CHC, CHB, ALD, NAFLD and mixed causes.
We extracted the following, when possible, from the pub-
lished studies and from the integrated database for the
sensitivity analyses: study design (prospective or retro-
spective); analytical procedures (fresh serum and compli-
ance with the recommended procedures or not); spectrum
of disease (patients with elevated or normal transami-
nases); co-morbidity (several morbidities including HCV,
HBV, alcohol consumption, HIV coinfection, presence/
absence of renal disease); and whether the study was per-
formed by the FT inventor group (yes, no, mixed groups
including inventor). Patient inclusion was never depend-
ent on the result of the non-invasive test under investiga-
tion.
Statistical analysis
Comparison of FT diagnostic values between different chronic liver 
diseases
The main end point was the FT value for the diagnosis of
advanced fibrosis (bridging fibrosis or stages F2, F3, F4
according to the METAVIR scoring system [15-17]), as
assessed by the area under the receiver operating charac-
teristics curve (AUROC)].
Comparison of FT diagnostic values between adjacent stages
The main endpoint was the comparison of the FT
AUROCs between adjacent stages: either between two
adjacent intermediate stages F2/F1 or between two adja-
cent extreme stages F4/F3 and vs. F1/F0.BMC Gastroenterology 2007, 7:40 http://www.biomedcentral.com/1471-230X/7/40
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Statistical methods
A significance level of 5% was used as the alpha risk. Each
estimate was given with its 95% confidence interval.
Comparisons of the odds ratio and of percentages
between strata were performed using their 95% confi-
dence interval (95% CI). The primary analysis was per
patient. In two studies patients were included twice, as
they had FT and biopsy once before and once after the
treatment; a sensitivity analysis was performed including
and excluding these studies.
We used a random effects model for the primary meta-
analysis to obtain a summary estimate for the AUROCs
with a 95% CI of FT compared with liver biopsy.
The AUROC was used as a measure of discrimination, esti-
mated using the empirical (non-parametric) method by
DeLong et al. [18], and was compared using the paired
method by Zhou et al. [19]. All analyses are performed on
NCSS software (Kaysville, Utah, USA) [20].
Sensitivity analyses done by comparing AUROCs were
planned for pre-specified items: study design (prospective
or retrospective); analytical procedures (fresh serum or
not); compliance with recommended analytical proce-
dures (yes or no); spectrum of disease (patients with ele-
vated or normal transaminases); year of study; co-
morbidity (several morbidities including HCV, HBV, alco-
hol consumption, HIV coinfection, overweight, diabetes,
hyperlipidemia, renal disease); whether the study was per-
formed by the FT inventor group (yes, no, mixed groups
including inventor).
Meta-analysis was performed twice, once according to the
absolute value of the observed AUROCs (ObAUROC) and
once according to the AUROCs standardized for the spec-
trum of fibrosis stages (AdAUROC). We previously dem-
onstrated that the AUROCs were highly related to the
difference between the mean fibrosis stages in the
advanced fibrosis and non advanced fibrosis groups
(DANA); the AdAUROC is the AUROC adjusted for the
difference of the observed DANA versus a standard DANA
of 2.5 fibrosis METAVIR units (DANA = 2.5 if there was a
uniform prevalence of 0.20 in each of the 5 stages); all the
AUROCs were adjusted to a DANA of 2.5 using the for-
mula: AdAUROC = ObAUROC + (0.1056) (2.5-
ObDANA)[11,12].
Liver biopsies
The recruiting method of the sampling has been detailed
in the previous publications. In the integrated database,
liver biopsies were processed using standard techniques. A
pathologist who was unaware of the biochemical markers
evaluated the fibrosis stage and necrosis grade according
to the METAVIR scoring system [15-17]. Fibrosis was
staged on a scale of 0 – 4: F0 no fibrosis, F1 portal fibrosis
without septa, F2 few septa, F3 numerous septa without
cirrhosis, and F4 cirrhosis. Biopsies were performed with
a 16-gauge Hepafix Luer Lock needle (Braun Melsungen)
in the Paris center and the Bordeaux center, and with var-
ious needles in the multicenter study from Marseille.aucs
according to the prevalence of fibrosis stages
Results
Databases
A total of 31 studies (one population = one study) pub-
lished in 25 articles between 2001 and 2007 were identi-
fied (Table 1) [3-8,21-39]; in one study, the AUROC was
unknown [27] and was not included, resulting in 30
included studies (Figure 1). These included 6,378 subjects
with both FT and biopsy (3,501 HCV, 1,457 HBV, 267
NAFLD, 429 ALD, and 724 mixed). One study including
208 patients with alcoholic liver disease focused on the
diagnostic value of the AshTest for the diagnosis of alco-
holic hepatitis [35] but the details concerning the
AUROCs of FT for the diagnosis of fibrosis, previously not
detailed in the original publication, were used in the
present overview (Table 1).
Individual data were available in 3,282 patients who con-
stituted the integrated data base: 2,431 HCV, 322 HBV,
267 NAFLD and 262 ALD (Table 2). Among the 3,282
patients included in the integrated database 875 patients
belong to independent studies (27%), 1,431 to mixed
(43%) and 976 (30%) to non-independent studies.
Comparison of FT diagnostic values between different 
chronic liver diseases
The mean of the observed AUROCs in published studies
was 0.80 (95% CI, 0.78–0.82) (Figure 2) and of the
AdAUROCs was 0.84 (95% CI, 0.83–0.86) (Figure 2).
There was a significant heterogeneity between studies for
the ObAUROCs (Cochran Q = 56; P = 0.001) but not for
the AdAUROCS (Cochran Q = 26 P = 0.19). There was no
significant difference between the ObAUROCs (Figure 1)
or AdAUROCs (Figure 3) in HCV patients compared to
other liver diseases (Table 2, and Table 3).
In the integrated data base, the mean FT ObAUROC was
0.79 (95% CI, 0.77–0.82) and the mean AdAUROC was
0.84 (0.82–0.86). There was no significant difference
between AdAUROCs in HCV patients compared to other
liver diseases. The only significant difference was a higher
ObAUROC in ALD than in HCV (P = 0.001) (Table 2).
Sensitivity analyses according to study characteristics are
detailed in Table 3 for meta-analysis and in Table 4 for the
integrated data base. There were no significant differences
according to liver disease, baseline transaminases level,
authors' independency, to the mean length of biopsy, theB
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Table 1: Characteristics of the FibroTest diagnostic studies for the staging of hepatic fibrosis in patients with chronic liver disease
First author [ref] Number 
Patients
Methodology Age Stage 
Prevalence
AUROC SE F0 (%) F1 (%) F2 (%) F3 (%) F4 (%) DANA Size mm Independent Guidelines 
and fresh
Biopsy FT 
median days
High risk 
profile $ (%)
HCV n = 20
Imbert-1, 2001 (21) 189 Prospective Single 
center Training cohort
47 F2F3F4 0.38 0.84 0.03 36 (18) 91 (44) 40 (20) 18 (9) 20 (10) 2.03 16 No Yes 0 NA
Imbert-2, 2001 (21) 134 Prospective Single 
center Validation 
cohort
48 F2F3F4 0.45 0.87 0.03 20 (15) 54 (40) 28 (21) 10 (7) 22 (16) 2.16 16 No Yes 0 NA
Poynard-1, 2001 (22) 299 Retrospective 
Randomized trial 
Multicenter
41 F3F4 Knodell 0.36 0.74 0.03 60 (20) 133 (44) 56** (17) 55 (17) 5 (2) 1.42 NA Mixed Yes NA NA
Poynard-2, 2003 (23) 352 Retrospective 
Randomized trial 
Multicenter Before 
treatment
45 F2F3F4 0.39 0.73 0.03 6 (2) 206 (59) 63 (18) 32 (9) 32 (9) 1.71 17 Mixed No 137 0 (0)
Poynard-3, 2003 (23) 352 Retrospective 
Randomized trial 
Multicenter After 
treatment
47 F2F3F4 0.32 0.77 0.03 15 (4) 222 (63) 64 (18) 25 (7) 26 (10) 1.73 17 Mixed No 12 0 (0)
Rossi, 2003 (24) 125 Prospective Multicenter 40 F2F3F4 0.38 0.74 0.05 25 (20) 52 (42) 26 (21) 13 (10) 9 (7) 1.95 NA Yes No 0 0 (0)
Myers-1, 2003 (25) 130 Retrospective Single 
center HCV-HIV Co-
infection
38 F2F3F4 0.45 0.86 0.04 17 (13) 55 (42) 22 (17) 19 (15) 17 (13) 2.15 NA No Yes < 180 NA
Castera, 2005 (26) 183 Prospective Single 
center
51 F2F3F4 0.38 0.84 0.03 0 (0) 47 (26) 53 (29) 37 (20) 46 (25) 1.95 17 Yes Yes 0 NA
Cales-2, 2005 (7) 120 Prospective Single 
center Validation 
cohort
44 F2F3F4 0.48 0.86 0.06 20 (17) 43 (36) 28 (3) 14 (12) 15 (13) 2.09 21 Yes No < 7 NA
Coletta, 2005 (27) 40 Prospective Multicenter 
PNALT
44 F2F3F4 0.35 NA 3 (8) 23 (58) 9 (23) 5 (13) 0 (0) 1.47 20 Yes NA 180 NA
Varaut-1, 2005 (28) 50 Retrospective Single 
center Dialysis patients
48 F2F3F4 0.42 0.53 0.04 1 (2) 28 (56) 11 (22) 8 (16) 2 (4) 1.61 19 Yes No < 180 2 (4)
Varaut-2, 2005 (28) 60 Retrospective Single 
center Kydney 
recipients
44 F2F3F4 0.44 0.71 0.04 10 (21) 21 (35) 17 (28) 10 (16) 2 (3) 1.84 19 Yes No < 180 2 (3.3)
Halfon, 2006 (29) 504 Prospective Multicenter 45 F2F3F4 0.45 0.79 0.02 58 (12) 216 (43) 110 (22) 91 (18) 29 (6) 1.87 15 Yes Yes 0 15 (3)
Sebastiani-1, 2006 (30) 65 Prospective PNALT 45 F2F3F4 0.39 0.71 0.04 18 (27) 22 (34) 12 (19) 6 (9) 7 (11) 2.21 18 Yes Yes 0 Excluded
Sebastiani-2, 2006 (30) 125 Prospective EALT 50 F2F3F4 0.71 0.81 0.03 6 (5) 30 (24) 53 (42) 15 (12) 21 (17) 1.83 18 Yes Yes 0 Excluded
Wilson, 2006 * (31) 115 Retrospective 
Multicenter 30% HIV
42 F2F3F4 0.38 0.74 0.05 39 (33) 36 (30) 33 (28) 8 (7) 3 (3) 1.87 11 Yes No Contemporaneous NA
Sene, 2006 (32) 138 Prospective Single 
center 
Cryoglobulinemia 
Vasculitis
58 F2F3F4 0.47 0.83 0.03 37 (27) 36 (26) 30 (22) 16 (12) 19 (14) 3.05 18 No Yes < 60 11 (8)
Halfon-2, 2007 (36) 158 Prospective Single 
center
41 F2F3F4 0.79 0.03 6 (4) 103 (65) 34 (22) 13 (8) 2 (1) 1.38 21 Yes Yes 0 NA
Leroy, 2007 (37) 180 Prospective Single 
center
44 F2F3F4 0.84 0.03 15 (8) 74 (41) 40 (22) 26 (14) 25 (14) 2.00 23 Yes Yes 0 NA
Grigorescu, 2007 (39) 206 Single center 47 F2F3F4 0.78 0.02 16 (8) 60 (29) 70 (34) 44 (21) 16 (8) 1.80 NA Yes Yes NA Excluded
HBV n = 4
Myers-2 (3) 209 Prospective and (42) 
Retrospective (167)
39 F2F3F4 0.29 0.78 0.04 76 (36) 72 (34) 32 (15) 10 (5) 19 (9) 2.31 18 No Yes 1 NA
Poynard-4, 2005 (4) 214 Prospective 40 F2F3F4 0.67 0.77 0.03 14 (8) 53 (25) 119 (24) 55 (26) 40 (19) 2.17 NA Mixed Yes 150 7 (3.2)
Sebastiani-3, 2007 (33) 110 Prospective 43 F2F3F4 0.85 0.04 15 (14) 20 (18) 40 (36) 13 (12) 22 (20) 2.19 17 Yes Yes 0 Excluded
Poynard-5, 2007 (34) 924 Retrospective 39 F2F3F4 0.76 0.02 21 (2) 596 (65) 160 (17) 69 (7) 78 (8) 1.77 13 Mixed Yes 90 80 excluded (8)
ALD n = 2
Naveau, 2005 (5) 221 Prospective One center 47 F2F3F4 0.64 0.84 003 16 (7) 65 (29) 48 (22) 24 (11) 68 (31) 2.34 15 Mixed Yes 9 4 (1.8)
Thabut, 2006 (35) 208 Prospective Two 
centers
51 F2F3F4 0.91 0.02 10 (5) 25 (12) 21 (10) 17 (8) 136 (65) 2.98 12 Mixed Yes 0 15 (7.2)
NAFLD n = 2
Ratziu-1, 2006 (8) 170 Prospective 53 F2F3F4 0.24 0.86 0.03 77 (45) 54 (31) 20 (12) 11 (7) 9 (5) 2.30 20 No Yes 0 5 (2.9)
Ratziu-2, 2006 (8) 97 Prospective 49 F2F3F4 0.15 0.75 0.04 26 (27) 40 (41) 15 (15) 12 (12) 4 (4) 2.04 18 Yes Yes 0 2 (2)
Mixed n = 3
Cales1, 2005 (7) 478 Prospective Single 
center HCV, HBV, ALD
45 F2F3F4 0.59 0.82 0.03 28 (6) 170 (36) 120 (25) 57 (12) 102 (21) 2.08 18 Yes No < 7 NA
Callewaert, 2004 (6) 106 Prospective HCV and 
ALD
NA F4 0.29 0.89 0.04 0 (0) 28 (26) 20 (19) 10 (9) 48 (45) 2.73 NA Yes Yes NA NA
Coco, 2007 (38) 164 Prospective HCV and 
HBV
50 F2F3F4 0.89 0.05 29 (18) 33 (20) 13 (8) 6 (4) 83 (51) 3.15 25 Yes Yes 90 NA
*Details for stages given out of 119 and not out of 115: ** half of Knodell F3 has been counted as METAVIR F2
NA: not available; PNALT: persistently normal ALT; EALT: Elevated ALT
$ High risk profile defined as hemolysis, Gilbert or acute inflammation; mean was 143/3,495 (4.1%)BMC Gastroenterology 2007, 7:40 http://www.biomedcentral.com/1471-230X/7/40
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interval serum-biopsy, and co-morbidity. Prospective
studies, and studies following guidelines were associated
with higher ObAUROCs but these differences were no
more significant for AdAUROCs. In the integrated data-
base fragmented biopsies were associated with higher
ObAUROC but this difference was no more significant for
AdAUROCs.
Comparison of FT diagnostic values between adjacent 
stages
The AUROC for the diagnosis of intermediate stages F2 vs.
F1 (0.66; 0.63–0.68, n = 2,055) was not different com-
pared to the extreme stages: F3 vs. F4 (0.69; 0.65–0.72, n
= 817) or F1 vs. F0 (0.62; 0.59–0.65, n = 1788). There
were also no differences between adjacent stages when the
AUROCs were compared for each chronic liver disease
(Table 5).
High risk profile
The overall prevalence of patients with high risk profile of
false positive or false negative (suspected Gilbert syn-
drome, hemolysis and acute inflammation) was 4.1%
(143/3,495; 95%CI 3.5%–4.8%) among the studies and
1.9% in the integrated data-base (47/2,532 95%CI 1.4%–
2.5%).
Discussion
This meta-analysis demonstrated that the diagnostic value
of FT was similar in the four most frequent chronic liver
diseases. This meta-analysis also demonstrated that the
diagnostic value of FT, as for liver biopsy, was similar
between all the adjacent fibrosis stages but without a spe-
cific "gray zone" or "inaccurate zone" between intermedi-
ate stages. FT, like biopsy, has lower diagnostic value to
discriminate between two adjacent stages than between
two extreme stages [17].
The advantages of the present study are the large number
of studies included, as well as the opportunity to analyze
an integrated database, which included the individual
characteristics of 3,282 (51%) patients out of 6,378
patients included in the published studies. This permitted
to better take into-account the variability factors associ-
ated with FT diagnostic value.
Comparison of FT diagnostic values between different 
chronic liver diseases
One limitation of the study is that the number of studies
and patients in non HCV related diseases is smaller than
those in HCV. However we analyzed a total of eleven stud-
ies including 2,877 non HCV or mixed causes, and 851
non-HCV patients in the integrated data base. Another
limitation was that there were few independent studies in
other chronic liver diseases (1 for HBV, 1 for NAFLD and
none for ALD). However two studies in HBV [4,34] and
two studies in ALD [5,35] were mixed and three inde-
Table 2: Characteristics of the integrated data-base and FibroTest diagnostic value in liver disease
Disease Number Age yr Biopsy 
Length
 mm
F0 (%) F1 (%) F2 (%) F3 (%) F4 (%) ObAUROC DANA AdAUROC High risk 
profile $ (%)
HCV 2,431 47 17 204 (8.4) 1123 (46.2) 531 (21.8) 298 (12.3) 275 (11.3) 0.77 0.75–0.79 1.92 0.83 0.81–0.85 26/1681 (1.5)
HBV 322 42 17 86 (26.7) 94 (29.2) 61 (18.9) 38 (11.8) 43 (11.4) 0.81 0.76–0.86 2.30 0.83 0.78–0.88 9/322 (2.8)
ALD 262 48 14 18 (6.9) 67 (25.6) 50 (19.1) 23 (8.8) 104 (39.7) 0.85 0.80–0.89* 2.52 0.85 0.80–0.89 5/262 (1.9)
NAFLD 267 51 19 102 (38.2) 94 (35.2) 35 (13.1) 23 (8.6) 13 (4.9) 0.81 0.74–0.86 2.21 0.84 0.77–0.89 7/267 (2.6)
All 3,282 47 17 410 (12.5) 1378 (42.0) 677 (20.6) 382 (11.6) 435 (13.3) 0.79 0.77–0.80 2.07 0.84 0.82–0.86 47/2,532 (1.9)
* P = 0.001 between HCV and ALD for ObAUROC, Non Significant for AdAUROC
Flow sheet of the included databases Figure 1
Flow sheet of the included databases.
35 Articles Excluded
One Article excluded
No AUROC
30 Population
Included
6,378 Subjects
In 24 Articles
31 Population
Pre Included
In 25 articles
66 Articles Identified
Published Populations
January 2001-August 2007
3,282 Patients Included
Consecutive Patients
Five Centers: Bordeaux,
Provence Cote d'Azur,
Paris, Clamart, Clichy
Individiual Data Base
Two Data BasesBMC Gastroenterology 2007, 7:40 http://www.biomedcentral.com/1471-230X/7/40
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pendent studies included HBV and ALD in their analyses
[6,7,38] with same results than in non-independent stud-
ies (Table 1).
To compare as well as possible the FT diagnostic value
according to liver diseases, we used the standardization of
the AUROCs, and sensitivity analysis in both the meta-
analysis and the integrated data base with individual data.
We applied the standardization of the observed AUROCs
according to the spectrum of fibrosis stages among
advanced and non advanced fibrosis. We recently demon-
strated that this standardization is mandatory for any
interpretation of AUROCs estimating the diagnostic value
of a fibrosis marker [12]. For instance, this method
allowed an adjustment to be made in the ObAUROCs of
FT according to the cause of liver disease, which had sig-
nificant difference in fibrosis stage spectrum. The signifi-
cant difference observed between ALD and HCV
ObAUROCs disappeared after adjustment (Table 2). In
HBV studies patients had lower DANA than in studies of
ALD patients. After standardization, the difference
between AUROCs was reduced by two (0.77 versus 0.88
before and 0.80 versus 0.86 after standardization) (Table
2).
These data are also in accordance with the similarities of
advanced fibrosis stages among chronic hepatitis C and B,
NAFLD and ALD. Despite differences in the dynamics of
fibrosis progression [40] and the initial fibrosis stages, the
bridging stages are very similar including cirrhosis and
were estimated in the same way by the METAVIR scoring
system for advanced fibrosis [40,41]. Fibrosis stages and
pathogenetic mechanisms are very similar in NAFLD and
ALD [42]. Repeated FT improved similar to fibrosis as esti-
mated by repeated biopsies during treatment for HCV
[22,23], HBV [4,34] and NAFLD [43]. The components of
the FT had similar modifications according to fibrosis
stages for these four chronic liver diseases [1,3,5,8].
The sensitivity analyses did not reveal any significant dif-
ferences between AdAUROCs according to all the other
characteristics analyzed (Table 3 and Table 4). Significant
differences or the absence of differences between ObAU-
ROCs could be due to confounding factors. A demonstra-
tive illustration is the artificially higher ObAUROCs for
fragmented versus non-fragmented biopsies. Because of a
higher prevalence of cirrhosis in patients with fragmented
biopsies, the DANA was higher than in patients with non-
fragmented biopsies [11]. This difference was no longer
seen after adjustment [Table 4).
Table 3: Sensitivity analyses of FibroTest diagnostic values according to published studies
Observed AUROC Standardized AUROCs
Characteristic (number of studies)
All (30) 0.80 0.78–0.82 0.84 0.83–0.86
Disease
HCV (19) 0.79 0.76–0.82 0.85 0.82–0.87
HBV (4) 0.77 0.74–0.81 0.80 0.77–0.84
ALD (2) 0.88 0.81–0.84 0.86 0.80–0.92
NAFLD (2) 0.81 0.70–0.91 0.84 0.76–0.92
Mixed (3) 0.86 0.81–0.91 0.85 0.80–0.93
Design
Prospective (19) 0.83 0.81–0.85* 0.86 0.84–0.88
Retrospective (11) 0.76 0.73–0.78 0.82 0.80–0.84
Authors
Independent (16) 0.80 0.77–0.83 0.85 0.82–0.88
Mixed (5) 0.76 0.73–0.80 0.83 0.81–0.86
Inventor (9) 0.83 0.79–0.87 0.84 0.81–0.88
Guidelines/Fresh
No (7) 0.77 0.72–0.79 0.83 0.80–0.86
Yes (23) 0.82 0.79–0.84** 0.84 0.83–0.86
Length biopsy
< 18 (6) 0.81 0.76–0.86 0.84 0.80–0.87
> = 18 (18) 0.81 0.78–0.84 0.85 0.83–0.87
Interval serum-biopsy
> 30 days (8) 0.79 0.74–0.84 0.81 0.78–0.84
< 30 (15) 0.80 0.78–0.83 0.85 0.83–0.87
Co-morbidity
No (21) 0.79 0.77–0.81 0.85 0.83–0.87
Yes (8) 0.83 0.78–0.88 0.83 0.80–0.87
* P = 0.001 ** P = 0.05BMC Gastroenterology 2007, 7:40 http://www.biomedcentral.com/1471-230X/7/40
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Comparison of FT diagnostic values between adjacent 
stages
There is still a controversy among experts concerning the
FT diagnostic value for "intermediate fibrosis stages". For
panel biomarkers including FT, Gebo et al. stated that
"One of the major limitations may be in the lack of relia-
ble identification and classification of the intermediate
stages of fibrosis"[9]. Bissell also stated that for panels
including FT "Their accuracy for intermediate fibrosis is
relatively poor." [44]. Rockey and Bissell stated that "Deci-
sion-making requires a test that differentiates minimal
disease [stage 0/1 fibrosis) from intermediate fibrosis
[stage 2/3). For this purpose, the current generation of
non-invasive tests falls short, and liver biopsy still is
needed for definitive staging" [45]. These statements are
not evidence-based.
Meta-analysis of the observed area under the ROC curves (AUROC) assessed in published studies of Fibrotest diagnostic value Figure 2
Meta-analysis of the observed area under the ROC curves (AUROC) assessed in published studies of Fibrotest diagnostic 
value. AUROCs were all significantly higher for Fibrotest than the random 0.50 value (upper panel) (P < 0.001). There was no 
significant difference between the different liver diseases.BMC Gastroenterology 2007, 7:40 http://www.biomedcentral.com/1471-230X/7/40
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The first error is stating that "liver biopsy is still needed for
definitive staging of intermediate stages". The entire liver
is certainly the gold standard but the liver biopsy is an
imperfect gold standard. The present overview of the 25
studies giving biopsy length, all performed in tertiary
centers, observed among 5,404 patients that the median
of mean biopsy length was 18 mm. For the two larger
studies including more than 500 patients (total 1,428) the
median was 14 mm and in the integrated data base the
mean was 17 mm out of 3,282. In our tertiary center a pro-
spective study observed in 1,769 patients that biopsy was
greater than 25 mm in only 16% (280/1769) of patients
[46].
A liver biopsy of 15 mm has an AUROC of 0.82 between
F1 and F2, being around 20% of false positives or false
negatives [17]. Therefore FT with an AUROC of 0.66 (usu-
ally described as a weak value when using a true gold
Meta-analysis of the standardized area under the ROC curves (AUROC) assessed in published studies of Fibrotest diagnostic  value Figure 3
Meta-analysis of the standardized area under the ROC curves (AUROC) assessed in published studies of Fibrotest diagnostic 
value. There was no significant difference between the different liver diseases.BMC Gastroenterology 2007, 7:40 http://www.biomedcentral.com/1471-230X/7/40
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standard) between F1 and F2 has a relative AUROC versus
the best AUROC possible of 0.66/0.82 = 0.80, which is in
the end acceptable for a non invasive test.
The second error is the confusion between intermediate
stages and adjacent stages. For any estimate of liver fibro-
sis, the diagnostic values (AUROCs) between adjacent
stages need to be assessed. There are no significant differ-
ences in the diagnostic values (AUROCs) for FT as demon-
strated in this study, or for liver biopsy as demonstrated
by Bedossa et al [17] according to intermediate stages as
opposed to extreme stages, with the AUROCs for all adja-
cent stages being similar. The same results have been
observed for all the combinations of stages in a previous
study [1] and with this database (data not showed).
The third error is assessing the diagnostic value of a
biomarker in a subpopulation of patients defined by liver
biopsy such as F2/F3 vs. F0/F1. The exclusion of F4
patients defined by a 15 mm biopsy will not exclude the
risk of false positives or false negatives of the remaining
non-F4. It is much more important to assess the spectrum
of fibrosis stage among the F0/F1 and F2/F3; if the
AUROCs are not standardized according to the DANA, the
ObAUROCs will be misleading [12]. This once again
underlines that assessing the AUROCs between all adja-
cent stages remains the best way, knowing that for the
"perfect" biomarker, the best possible achievable AUROC
is 0.82 for a 15 mm biopsy.
There are also different methodological approaches for
the overview of fibrosis markers. Parkes et al. arbitrarily
defined an "inaccurate" zone of a marker when it "cannot
reliably attribute result for tests as tests perform with
lower sensitivities/specificities at thresholds, where posi-
tive predictive value < 90%, negative predictive value >
95%" [47]. There is no rationale for choosing these
thresholds, but this definition could be acceptable if a true
gold standard existed. This is not the case for fibrosis
markers. If this definition is applied to 15 mm liver biop-
sies, the biopsy will be inaccurate in 40% of cases for a
diagnosis between F1 and F2.
The only significant difference identified using AUROCs
between adjacent stages (Table 5) was for HBV versus
ALD. The obAUROC for ALD was particularly high and
this should be validated in population with greater sam-
ple size.
High risk profile
"The observed high risk profile of FT in the published
studies (4.1%) and in the integrated database (1.9%) were
concordant with the post marketing analyses finding
(2.1%) in 32,527 consecutive tests [2,46]. In these ana-
lyzes there were 272 cases (0.8%) with a high-risk profile
of false positives, for which the other components were
not concordant in favor of significant fibrosis. Patients
with extremely low haptoglobin, particularly when the
rest of the exams were hardly modified, could have had
hemolysis. A high-risk profile of false positives due to pos-
sible Gilbert syndrome was observed in 409 (1.3%) cases.
In the presence of acute inflammation (i.e., sepsis or acute
hemolysis), FT analysis must be postponed [2]."
Conclusion
This study suggests that FT could be used as an alternative
to liver biopsy in the four more common chronic liver dis-
eases: HCV, HBV, NAFLD and ALD. Neither biomarkers
nor biopsy are sufficient alone to take definitive decision
in a given patient and all the clinical and biological data
must be taken into account.
Table 5: FibroTest diagnostic values between adjacent stages
Observed AUROC
Adjacent stages
F1 vs. F0 (1,788) 0.62 0.59–0.65
HCV (1,327) 0.64 0.60–0.68
HBV (180) 0.64 0.56–0.72
ALD (85) 0.47 0.32–0.60
NAFLD (196) 0.53 0.45–0.61
F2 vs. F1(n = 2,055) 0.66 0.63–0.68
HCV (1,654) 0.66 0.63–0.69
HBV (155) 0.63 0.53–0.71
ALD (117) 0.65 0.53–0.74
NAFLD (129) 0.69 0.57–0.78
F3 vs. F2 (n = 1,059) 0.67 0.64–0.70
HCV (829) 0.66 0.62–0.69
HBV (99) 0.78 0.67–0.86
ALD (73) 0.66 0.50–0.77
NAFLD (58) 0.69 0.52–0.80
F4 vs F3 (817) 0.69 0.65–0.72
HCV (573) 0.66 0.61–0.70
HBV (81)* 0.54 0.40–0.65
ALD (127)* 0.82 0.69–0.90
NAFLD (36) 0.71 0.45–0.86
* P = 0.001 between HBV and ALD
Table 4: Sensitivity analyses of FibroTest diagnostic values 
according to individual data
Characteristic 
(number of patients)
Observed 
AUROC
DANA Adjusted 
AUROC
Length biopsy
< 25 mm (2,446) 0.80 0.78–0.82 2.10 0.84 0.82–0.86
> = 25 mm (492) 0.77 0.72–0.81 1.91 0.83 0.78–0.87
More than 2 fragments
Yes (575) 0.86 0.82–0.89* 2.45 0.87 0.83–0.90
No (606) 0.78 0.73–0.81 2.05 0.83 0.78–0.86
Normal baseline ALT
No (1,833) 0.80 0.78–0.82 2.16 0.84 0.82–0.86
Yes (493) 0.79 0.74–0.84 2.39 0.81 0.76–0.86
*P = 0.002BMC Gastroenterology 2007, 7:40 http://www.biomedcentral.com/1471-230X/7/40
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However, due to the dramatically insufficient risk-benefit
ratio of biopsy (coefficient variation 40%, 0.3% severe
adverse events and 3/10,000 mortality), it is surprising
that many leaders and associations in the field of hepatol-
ogy still recommend liver biopsy as the first line investiga-
tion for millions of people exposed to the risk of fibrosis.
This study reinforced our previous conclusion [48] that,
based on current evidence, a wise recommendation would
be a moratorium on liver biopsy as a first line procedure
while awaiting studies demonstrating its cost-utility ver-
sus that of biomarkers. Biopsy as a second line estimate of
liver injury should still be indicated for intricate diseases
or clinicobiological discordances.
Practices are evolving rapidly and in France a nationwide
survey recently found that among 546 hepatologists, 81%
used non-invasive biomarker (FibroTest-ActiTest) and
32% used elastography, with a dramatic decrease in the
use of liver biopsy for more than 50% of patients with
chronic hepatitis C, and with a subsequent increase in the
number of patients treated [49]. FibroTest is available in
more than 50 countries [50] and the cost varies (from 100
to 300 euros per country) according to the price of the five
components and the price of algorithms. In France the
cost of the components was covered by social security
since 2002 and the algorithms reimbursement has been
approved in December 2006 [51].
A recent overview by French health authorities officially
approved non invasive biomarkers FibroTest and elastog-
raphy (Fibroscan) as first line estimates of fibrosis in
patients with chronic hepatitis C, recommended reim-
bursement by social security and approved liver biopsy
only as second line estimate in case of discordance or non
interpretability of non invasive markers. An updated over-
view is pending for other chronic liver diseases at the end
of 2007 [50].
Competing interests
TP is a consultant and has a capital interest in Biopredic-
tive, the company marketing FT, and MM is a full time
employee of Biopredictive.
Biopredictive had no role in the study design, data collec-
tion, data analysis, data interpretation, or writing of the
report. The corresponding author had full access to all the
data in the study and had final responsibility for the deci-
sion to submit for publication.
Authors' contributions
TP conceived the study, performed the statistical analysis,
and wrote the manuscript. RM, PH, LC, VR, FIM, SN, DT,
DL, FZ, MB, PC, MM, and VdL participated in the coordi-
nation of the study, data monitoring and drafted the man-
uscript. All authors read and approved the final
manuscript.
Acknowledgements
"Association pour la Recherche sur les Maladies Hépatiques et Virales" for 
support in the collection of data.
References
1. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP,
Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B: Over-
view of the diagnostic value of biochemical markers of liver
fibrosis (FibroTest, HCV-Fibrosure) and necrosis (ActiTest)
in patients with chronic hepatitis C.  Comp Hepatol 2004, 3:8.
2. Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V: FibroTest-
FibroSURE:towards a universal biomarker of liver fibrosis?
Expert Rev Mol Diag 2005, 5:15-21.
3. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bis-
mut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard
T: Prediction of liver histological lesions with biochemical
markers in patients with chronic hepatitis B.  J Hepatol 2003,
39:222-230.
4. Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P,
Landais P, El Hasnaoui A, Slama A, Blin P, Thibault V, Parvaz P, Munte-
anu M, Trepo C: Longitudinal assessment of histology surro-
gate markers (Fibrotest-Actitest) during lamivudine therapy
in patients with chronic hepatitis B infection.  Am J Gast 2005,
100:1970-1980.
5. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous
D, Beuzen F, Capron F, Thabut D, Munteanu M, Chaput JC, Poynard
T: Biomarkers for the prediction of liver fibrosis in patients
with chronic alcoholic liver disease.  Clin Gastroenterol Hepatol
2005, 3:167-174.
6. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe
J, Contreras R: Noninvasive diagnosis of liver cirrhosis using
DNA sequencer-based total serum protein glycomics.  Nature
Med 2004, 10:429-434.
7. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC,
Konate A, Gallois Y, Ternisien C, Chevailler A, Lunel F: A novel
panel of blood markers to assess the degree of liver fibrosis.
Hepatology 2005, 42:1373-1381.
8. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bony-
hay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, De
Ledinghen V, Poynard T, the LIDO Study Group and the CYTOL
Study Group: Diagnostic value of biochemical markers (Fibro-
Test-FibroSURE) for the prediction of liver fibrosis in
patients with non-alcoholic fatty liver disease.  BMC Gastroen-
terology 2006, 6:6.
9. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G,
Ghanem KG, El-Kamary SS, Sulkowski M, Bass EB: Role of liver
biopsy in management of chronic hepatitis C: A systematic
review.  Hepatology 2002, 36:S161-S172.
10. Sebastiani G, Alberti A: Non invasive fibrosis biomarkers reduce
but not substitute the need for liver biopsy.  World J Gastroen-
terol 2006, 12:3682-3694.
11. Poynard T, Halfon P, Castera L, Charlotte F, Bail BL, Munteanu M,
Messous D, Ratziu V, Benhamou Y, Bourliere M, Ledinghen VD, the
Fibropaca group: Variability of the area under the receiver
operating characteristic curves in the diagnostic evaluation
of liver fibrosis markers: impact of biopsy length and frag-
mentation.  Aliment Pharmacol Ther 2007, 25:733-739.
12. Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu
V, Benhamou Y, Bourliere M, de Ledinghen V, FibroPaca Group:
Standardization of ROC curve areas for diagnostic fvaluation
of liver fibrosis markers based on prevalences of fibrosis
Stages.  Clin Chem 2007, 53:1615-1622.
13. Bossuyt PM, Reitsma JB, Bruns DE: Towards complete and accu-
rate reporting of studies of diagnostic accuracy: the STARD
initiative.  Clin Radiol 2003, 58:575-580.
14. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR: Publication
bias in clinical research.  Lancet 1991, 337:867-872.
15. The French METAVIR Cooperative Study Group: Intraobserver
and interobserver variations in liver biopsy interpretation in
patients with chronic hepatitis C.  Hepatology 1994, 20:15-20.BMC Gastroenterology 2007, 7:40 http://www.biomedcentral.com/1471-230X/7/40
Page 11 of 11
(page number not for citation purposes)
16. Bedossa P, Poynard T: An algorithm for the grading of activity
in chronic hepatitis C. The METAVIR Cooperative Study
Group.  Hepatology 1996, 24:289-293.
17. Bedossa P, Dargère D, Paradis V: Sampling variability of liver
fibrosis in chronic hepatitis C.  Hepatology 2003, 38:1449-1457.
18. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the
areas under two or more correlated receiver operating
characteristic curves: a nonparametric approach.  Biometrics
1988, 44:837-45.
19. Zhou X, Obuchowski N, McClish D: Statistical Methods in Diagnostic
Medicine I edition. John Wiley & Sons, New York; 2002. 
20. Hintze JL: NCSS 2007 User Guide. Number Cruncher Statis-
tical Systems software.  NCSS, Kaysville, Utah 2007.
21. Imbert-Bismut F, Ratziu V, Laurence Pieroni L, Charlotte F, Ben-
hamou Y, Poynard T, MULTIVIRC Group: Biochemical markers of
liver fibrosis in patients with hepatitis C virus infection: a
prospective study.  Lancet 2001, 357:1069-1075.
22. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli
J, Messous D, Degos F: Biochemical markers of liver fibrosis in
patients infected by Hepatitis C Virus: Longitudinal valida-
tion in a randomized trial.  J Viral Hepatitis 2002, 9:128-133.
23. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J: Bio-
chemical surrogate markers of liver fibrosis and activity in a
randomized trial of peginterferon alfa-2b and ribavirin.  Hepa-
tology 2003, 38:481-492.
24. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, MacQuillan
G, Speers D, Jeffrey G: Validation of the FibroTest biochemical
markers score in assessing liver fibrosis in hepatitis C
patients.  Clin Chem 2003, 49:450-454.
25. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Char-
lotte F, Ratziu V, Bricaire F, Katlama C, Poynard T: Serum bio-
chemical markers accurately predict liver fibrosis in HIV and
hepatitis C virus-coinfected patients.  AIDS 2003, 17:1-5.
26. Castéra L, Vergniol J, Foucher J, Brigitte Le Bail B, Chanteloup E,
Haaser M, Darriet M, Couzigou P, de Lédinghen V: Prospective
comparison of transient elastography, Fibrotest, APRI and
liver biopsy for the assessment of fibrosis in chronic hepatitis
C.  Gastroenterology 2005, 128:343-350.
27. Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, Pirisi
M: Value of two noninvasive methods to detect progression
of fibrosis among HCV carriers with normal aminotrans-
ferases.  Hepatology 2005, 42:838-845.
28. Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas
B, Imbert Bismuth F, Lebray P, Pol S: Diagnostic accuracy of the
fibrotest in hemodialysis and renal transplant patients with
chronic hepatitis C virus.  Transplantation 2005, 80:1550-1555.
29. Halfon P, Bourliere M, Deydier R, Portal I, Renou R, Bertrand J, Trana
A, Rosenthal A, Rotily M, Sattonet A: Independent prospective
multicenter validation of biochemical markers (Fibrotest-
Actitest) for the prediction of liver fibrosis and activity in
patients with chronic hepatitis C.  Am J Gastro 2006,
101:547-555.
30. Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, Ferrari
A, Alberti A: Stepwise combination algorithms of non-invasive
markers to diagnose significant fibrosis in chronic hepatitis
C.  J Hepatol 2006, 44:686-93.
31. Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R,
Mehta S, Kirk GD, Nelson K, Afdhal N, Thomas DL: Progression of
liver fibrosis among injection drug users with chronic hepati-
tis C.  Hepatology 2006, 43:788-95.
32. Sène D, Limal N, Djamila Messous D, Ghillani-Dalbin P, Charlotte F,
Halfon P, Jean-Marie Thiollière JM, Piette JC, Imbert-Bismut F, Halfon
P, Poynard T, Cacoub P: Biological markers of liver fibrosis and
activity as non-invasive alternatives to liver biopsy in
patients with chronic hepatitis C and associated mixed cry-
oglobulinemia vasculitis.  Clin Biochem 2006, 39:715-721.
33. Sebastiani G, Vario A, Guido M, Alberti A: Sequential algorithms
combining non-invasive markers and biopsy for the assess-
ment of liver fibrosis in chronic hepatitis B.  World J Gastroen-
terol 2007, 13:525-731.
34. Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Goodman Z, Ratziu V,
Benhamou Y, Brosgart CL, Adefovir Dipivoxil 437 and 438 Study
Groups: Impact of adefovir dipivoxil on liver fibrosis and activ-
ity assessed with FibroTest-ActiTest in patients with chronic
hepatitis B infection.  Abstract EASL, J Hepatol 2007, 46:S298.
35. Thabut D, Naveau S, Charlotte F, Massard J, Ratziu V, Imbert-Bismut
F, Cazals-Hatem D, Abella A, Messous D, Beuzen F, Munteanu M,
Taieb J, Moreau R, Lebrec D, Poynard T: The diagnostic value of
biomarkers (AshTest) for the prediction of alcoholic steato-
hepatitis in patients with chronic alcoholic liver disease.  J
Hepatol 2006, 44:1175-85.
36. Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D,
Tran A, Botta D, Renou C, Brechot MC, Degott C, Paradis V: Com-
parison of test performance profile for blood tests of liver
fibrosis in chronic hepatitis C.  J Hepatol 2007, 46:395-402.
37. Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P,
Morel F, Zarski JP: Prospective comparison of six non-invasive
scores for the diagnosis of liver fibrosis in chronic hepatitis C.
J Hepatol 2007, 46:775-782.
38. Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P,
Bonino F, Brunetto MR: Transient elastography: a new surro-
gate marker of liver fibrosis influenced by major changes of
transaminases.  J Vir Hep 2007, 14:360-369.
39. Grigorescu M, Rusu M, Neculoiu D, Radu C, Aerban A, Caþanao M,
Grigorescu MD: The FibroTest Value in Discriminating
between Insignificant and Significant Fibrosis in Chronic
Hepatitis C Patients. The Romanian Experience.  Gastrointestin
Liver Dis 2007, 16:31-37.
40. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH,
Myers RP, Muntenau M, Ratziu V, Ma nns M, Vogel A, Ca pron F,
Chedid A, Bedossa P, PANFIBROSIS Group: A comparison of
fibrosis progression in chronic liver diseases.  J Hepatol 2003,
38:257-265.
41. Michalak S, Rousselet MC, Bedossa P, Pilette C, Chappard D, Oberti
F, Gallois Y, Cales P: Respective roles of porto-septal fibrosis
and centrilobular fibrosis in alcoholic liver disease.  J Pathol
2003, 201:55-62.
42. Lieber CS: CYP2E1: from ASH to NASH.  Hepatol Res 2004,
28:1-11.
43. Munteanu M, Poynard T, Charlotte F, Jacqueminet S, Messous D,
Podevin P, Serfaty L, Bruckert E, Grimaldi A, Ratziu V: Utility of a
combination of non-invasive biomarkers (Fibromax) in
assessing the efficacy of rosiglitazone in a one year rand-
omized, double-blind trial in non alcoholic steatohepatitis.
Abstract EASL, J Hepatol 2007, 46:S298.
44. Bissell MD: Assessing fibrosis without a liver biopsy: are we
there yet?  Gastroenterology 2004, 127:1847-1849.
45. Rockey DC, Bissell MD: Noninvasive measures of liver fibrosis.
Hepatology 2006, 43:S113-S120.
46. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le
Calvez S, Messous D, Thibault V, Benhamou Y, Moussalli J, Ratziu V:
Prospective Analysis of Discordant Results between Bio-
chemical Markers and Biopsy in Patients with Chronic Hep-
atitis C.  Clin Chem 2004, 50:1344-1355.
47. Parkes J, Indra Neil Guha IN, Roderick P, Rosenberg W: Perform-
ance of serum marker panels for liver fibrosis in chronic hep-
atitis C.  J Hepatol 2006, 44:462-474.
48. Poynard T, Ratziu V, Benhamou Y, Thabut D, Moussalli J: Biomark-
ers as a first-line estimate of injury in chronic liver diseases:
time for a moratorium on liver biopsy?  Gastroenterology 2005,
128:1146-1148.
49. Castera L, Denis J, Babany G, Roudot-Thoraval F: Evolving prac-
tices of non-invasive markers of liver fibrosis in patients with
chronic hepatitis C in France: Time for new guidelines?  J
Hepatol 2007, 46:528-529.
50.  [http://www.biopredictive.com].
51. La Haute Autorité de Santé (HAS) in France: The HAS recommen-
dations for the managemeMonant of the chronic hepatitis C
using non-invasive biomarkers.   [http://www.has-sante.fr/portail/
display.jsp?id=c_476486].
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-230X/7/40/pre
pub